{"name":"Immuneering Corporation","slug":"immuneering","ticker":"IMRX","exchange":"NASDAQ","domain":"immuneering.com","description":"Immuneering Corporation is a precision oncology company focused on developing innovative treatments for cancer. The company's top drugs include [list of major drugs]. Immuneering's therapeutic focus is on [list of therapeutic areas].","hq":"Cambridge, MA","founded":0,"employees":"","ceo":"Benjamin Zeskind","sector":"Precision Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$120M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"IMR-687 patent cliff ($X.XB at risk)","drug":"IMR-687","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Immuneering Corporation reported its fourth quarter and full year 2023 financial results, with revenue of $X.X million and a net loss of $Y.Y million.","drugName":"","sentiment":"neutral"},{"date":"2023-12-15","type":"deal","headline":"Immuneering Announces Collaboration with [Partner Company]","summary":"Immuneering Corporation announced a collaboration with [Partner Company] to develop new cancer treatments.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQaVN3Y0VfM2dFOUlNRlAxWlEybkRsWFBLTE56VkFvWjhrdkdFMUdHOE5MWERndUZXRVJCSXlxSWdyWE9pZlRabHFoZWZqSXl4WlVLcjRJVXlkQWM1NUxnd0w3SFZZS1p6RXBTRXQ1YmtvV3RTZG9BZm5FWDdqamx4X1drekxEMnE4bGd4Slc2clZaT2xJN0VFMDJ4T2hnemRQbjNIaEVXTFh2dERqbmV3N1dqdmNSa1dpV25jenBHR3FRdHRTNWJGSmJtQQ?oc=5","date":"2026-03-09","type":"pipeline","source":"24/7 Wall St.","summary":"X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - 24/7 Wall St.","headline":"X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention - 24/7 Wall St.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxQMDNrWVJ2cFVEVjhLbzd2cE11bmJseTVkSTY5TXUxMFVoT2RtemxnMVZhWkRuWWVQSkkzOV9GdDNubnEyVjY3VGNVaHd6NHR3WTRmRXJJZGN3Vk93ZHhuQkNaMV9xd01Dd2c5aDRiXzd6Xzl0T1hjbXNQdzlDQThwa1psc2RWN0EyNnM2T3V1VHRPRzVmUXBzb2FhUGdGM2hqZXBZek5nQTdEdFN1Q2R1SXVxeGNkc1pKVFgySUlMWHYydjJ4bHZWamJKX1RreFA2NTlma2ZLTklwWjdtSmNRdEgyTzZ6LWozTTFJN1VYQTR0eDlGQzdnd21zY0ZWdmZTVy1xMjctc2U?oc=5","date":"2026-01-08","type":"pipeline","source":"Benzinga","summary":"Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre - Benzinga","headline":"Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQYTVYZnVIak55UmhiSXhpbzZJdUY3czNmb1ZjYTBER2xPWXJPQ0NBemxvYUtaQXBJb05NVGRYSzJoeVZEeDZMMG4zTTctV0FMOXVtUTVzMUZXMW5VT28tZ0o3c3lJNlpia2FFd3d2dzZVNS1xUUlLS3JlN2RjTkU0LUYxNTJRb2FrUmhsZmItNmtBMlNNdXBrbWhNOFIwdTZRV3RMRFp3d0syXzNBaTR0cQ?oc=5","date":"2026-01-08","type":"regulatory","source":"TechStock²","summary":"Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update - TechStock²","headline":"Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update - TechStock²","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-27","type":"pipeline","source":"simplywall.st","summary":"Institutional investors control 36% of Immuneering Corporation (NASDAQ:IMRX) and were rewarded last week after stock increased 19% - simplywall.st","headline":"Institutional investors control 36% of Immuneering Corporation (NASDAQ:IMRX) and were rewarded last week after stock inc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNLVdfSEF4d19LT01QZnFsWG9hVTkxWUxqMXlKS0tSSXY5NFl0Mng4MUJTdDRoM1pubEFYbW1FWnpzWHJ2QjkxakE5MHE2THBSc2hLcHJXcDMzUFZVR0pRWm9ZclVOOHIwdG5HMWJDdHRpZXBrMC1teGJmYTdLeE9NcVVvaTMxS0cyR2NGay1DSHpOTmdWR0JUVkJiYU82QQ?oc=5","date":"2025-12-12","type":"pipeline","source":"investingnews.com","summary":"Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance - investingnews.com","headline":"Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1BNGxZOFR6bno4YWZJUEFubVRTbUR6ejVZR3d4a1p0Z1VTZ21kaFYzdDg1YWliYVk3eU1FUWNwRlRIc2ptVzA1N1JsSmtsUGNpMHJIWlRPenlsb2JvZzd0cHBTVGsxTlotUWxKbWF6YXp0U1d3QnF5c3ZOOA?oc=5","date":"2025-11-10","type":"earnings","source":"Yahoo Finance","summary":"Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? - Yahoo Finance","headline":"Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNWTVKRzBhWVI5WFFXZFQzZ1Y2YmhCWFFDRXl4bk1UaW5UY3lhU1VwbWxXSF9RQlNpMkZQOV9Fc2JBb0ZoSFFjMlN2TXRYRkpEYzlQbldkT0dJY1JGV2hyRmJwZjFyNTR2SE84QlE0a3hKa0FSMzZBODYweGlWRHBSUlpxQ3UzdzJkc2d0T3lpNHhoTkVQR2dLMGY1RQ?oc=5","date":"2025-10-12","type":"pipeline","source":"Seeking Alpha","summary":"SA Asks: What's the most attractive biotech stock right now? - Seeking Alpha","headline":"SA Asks: What's the most attractive biotech stock right now?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQVlpWWDNmd0xhVXBPd0Q0Rl9aVlphalk5cjNmUlEwZjZ3Q1p5RzQ2QndBUmVzd2s5MUo2RXJoNUtaTktXTFJoQk1MblRYRnJHaEVfR0lDRUVXNE9PQXc0M3lvWjRBTHBReFRFTWJTcEZzeXpPZjJ6WXd6TlRPazBvUWstbXpHSFRIZ2x3QURHbkpmVUtJclpkVjNuQjBlYUx0cFpzQTFLVkhidzNELTFHNFcyQ0NWaWxydnV0Wg?oc=5","date":"2025-09-25","type":"pipeline","source":"Investing.com","summary":"Immuneering prices $175 million public offering at $9.23 per share - Investing.com","headline":"Immuneering prices $175 million public offering at $9.23 per share","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQMUpYRXgwVUNpOThnZzQxVVF3SF9oTXN2WlRJdTFMdE5IN2U2UW9talFDOVZsYWxiM3ZOUHFnVGNOdmVJRXliVU9XMHlIdUZXT3VRTjlZTVlKT0ZqLU9jQnlfcl9jdzRpYkg3dERISVZ6Y0taSnhVRm9Ib3M2X2daV2dHako0YU5xcXZPSDdRWG9yVGppOGpXTE1VNjZ5MlI2?oc=5","date":"2025-08-26","type":"pipeline","source":"Seeking Alpha","summary":"Immuneering Corporation: Ripping On A Questionable Catalyst (NASDAQ:IMRX) - Seeking Alpha","headline":"Immuneering Corporation: Ripping On A Questionable Catalyst (NASDAQ:IMRX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9jd0w5Y3UzbU4wS2V5a3FLaXBVRWp6MVNoQWI2a3ZreC1odzJRMnZHS3Z5LThfM1JCQnlTaXZ0dGdIeUYwejZ1QUg0RkFXUjEtM0pMcE04OEJQaEhSZkpOaHFGLXNNbjJSaTBCbEc3Ymh6NjFRNi04UXFpSWQyQjQ?oc=5","date":"2025-08-26","type":"pipeline","source":"Yahoo Finance","summary":"Immuneering Stock Rises 21.7% on Supply Agreement With LLY - Yahoo Finance","headline":"Immuneering Stock Rises 21.7% on Supply Agreement With LLY","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNbU5yM094Q0RDaHQwTzRxRjJnZ043bmt6M1JfM3YzZEpHR0NZdUYxeEhYaHUzWHFBVnBVMGhVUVdtRm5vOXlTYUdOV3lnRUtIeDNya0RMZWptM0JkX19QXzFDSjFjeVg3RzhBQXBYRXhWSE1iajZMM3VBMnBfbTdCWjdKejdqNE52d3JBZXZ2MXNwLUhnU0c5N2JYUHE1TUk0N1VTNVliREdVNHJ4WnktYzcwUTNPbS1xM29zUU1TaTg?oc=5","date":"2025-06-16","type":"trial","source":"Stock Titan","summary":"Critical Phase 2a Data Coming: Immuneering's New Pancreatic Cancer Drug Could Change First-Line Treatment - Stock Titan","headline":"Critical Phase 2a Data Coming: Immuneering's New Pancreatic Cancer Drug Could Change First-Line Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1nZlJRbXg5NmJIaWdtRFRoVTZXTXRJMlBzZWJNbEZ6VUhNTFpxQzdlbnIwWkl0RzJVOXpodTU3eUtmUmxNVEdkYzZkYVB2R0Q4NERF?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"IMRX Stock Price, News & Analysis - Stock Titan","headline":"IMRX Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[{"drugName":"IMR-687","drugSlug":"imr-687","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US"}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Foundation Medicine","Guardant Health","Invitae"],"therapeuticFocus":["Precision Oncology"],"financials":null,"yahoo":null}